Risk of Future Type 2 Diabetes Mellitus in Patients Developing Steroid-Induced Hyperglycemia During Hospitalization for Chronic Obstructive Pulmonary Disease Exacerbation

被引:10
|
作者
Upadhyay, Jagriti [1 ]
Trivedi, Nitin [2 ,3 ,4 ]
Lal, Amos [5 ]
机构
[1] Beth Israel Deaconess Med Ctr, Dimock Community Hlth Ctr, Div Endocrinol, 55 Dimock St, Boston, MA 02215 USA
[2] St Vincent Hosp, Div Endocrinol & Metab Med, Worcester, MA 01604 USA
[3] St Vincent Hosp, Dept Med, Internal Med Residency, Worcester, MA 01604 USA
[4] Univ Massachusetts, Med Sch, Worcester, MA 01605 USA
[5] Mayo Clin, Div Pulm & Crit Care Med, Dept Med, 200 1st St SW, Rochester, MN 55902 USA
关键词
Glucocorticoids; Type 2 diabetes mellitus; COPD; Hyperglycemia; Prediabetes; RESPIRATORY-FAILURE; GLUCOSE; MANAGEMENT; GLUCOCORTICOIDS; PREVALENCE; THERAPY; DOSAGES;
D O I
10.1007/s00408-020-00356-z
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Objective We evaluated the future risk of developing impaired glucose tolerance and type 2 diabetes mellitus (T2DM) in patient without T2DM who develop hyperglycemia with short-term systemic glucocorticoid therapy during hospitalization. Methods Retrospective analysis was performed on charts of non-diabetic patients admitted with COPD exacerbation and treated with a course of high dose systemic corticosteroid during hospitalization. Patients with BMI over 40 kg/m(2), endocrinopathy and on medications that could impair glucose tolerance were excluded. Patient data were collected for 1 year after initial hospitalization. Diagnosis of T2DM or IGT was based on the ADA criteria. 311 charts were reviewed, of which 64 patients met our inclusion criteria. Depending on the blood glucose readings during hospitalization, the patients were categorized into two groups: hyperglycemic (> 140 mg/dL; n = 42) and normoglycemic (<= 140 mg/dL; n = 22). Results In the hyperglycemic group, 17/42 (40%) patients developed prediabetes and 5/42 (12%) developed T2DM on follow-up. Interestingly, none of the patients developed IGT or T2DM in the normoglycemic group. Both the groups were well matched in terms of family history of DM, history of hypertension, hyperlipidemia, BMI > 25 kg/m(2), weight change, tobacco and alcohol use, corticosteroid therapy duration, and cumulative steroid dose. After adjusting for all these risk factors, on logistic regression analysis, hyperglycemic patients had 37 times higher chance of developing IGT, compared to normoglycemic patients (p = 0.003). Conclusions Our study suggests that patients without T2DM with acute exacerbation of COPD who develop steroid-induced hyperglycemia in response to systemic corticosteroid treatment have an increased risk for developing future IGT or T2DM. Bigger studies are needed to support our findings since results drawn from our study have the limitations of smaller sample size (wider confidence interval) in a single center.
引用
收藏
页码:525 / 533
页数:9
相关论文
共 50 条
  • [1] Risk of Future Type 2 Diabetes Mellitus in Patients Developing Steroid-Induced Hyperglycemia During Hospitalization for Chronic Obstructive Pulmonary Disease Exacerbation
    Jagriti Upadhyay
    Nitin Trivedi
    Amos Lal
    [J]. Lung, 2020, 198 : 525 - 533
  • [2] Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease
    Rosario Amaya-Villar
    Jose Garnacho-Montero
    Jose Luis García-Garmendía
    Juan Madrazo-Osuna
    M. Carmen Garnacho-Montero
    Rafael Luque
    Carlos Ortiz-Leyba
    [J]. Intensive Care Medicine, 2005, 31 : 157 - 161
  • [3] Steroid-induced myopathy in patients intubated due to exacerbation of chronic obstructive pulmonary disease
    Amaya-Villar, R
    Garnacho-Montero, J
    García-Garmendía, J
    Madrazo-Osuna, J
    Garnacho-Montero, MC
    Luque, R
    Ortiz-Leyba, C
    [J]. INTENSIVE CARE MEDICINE, 2005, 31 (01) : 157 - 161
  • [4] Impact of diabetes mellitus on the risk of severe exacerbation in patients with chronic obstructive pulmonary disease
    Figueira Goncalves, Juan Marco
    Garcia Bello, Miguel angel
    Golpe, Rafael
    Alonso Jerez, Juan Luis
    Garcia-Talavera, Ignacio
    [J]. CLINICAL RESPIRATORY JOURNAL, 2020, 14 (12): : 1208 - 1211
  • [5] Diabetes and steroid-induced hyperglycemia in patients with COPD exacerbation: Prevalence and clinical outcome
    Gambhir, Rashi
    Hemrajani, Dolly
    Roediger, Laurian
    Smiley, Dawn
    Peng, Limin
    Osburne, Robert
    Umpierrez, Guillermo E.
    [J]. DIABETES, 2008, 57 : A138 - A138
  • [6] The Impact of Diabetes Mellitus in Patients with Chronic Obstructive Pulmonary Disease (COPD) Hospitalization
    Gunasekaran, Kulothungan
    Murthi, Swetha
    Elango, Kalaimani
    Rahi, Mandeep Singh
    Thilagar, Bright
    Ramalingam, Sathishkumar
    Voruganti, Dinesh
    Paramasivam, Vijaya Kumar
    Kolandaivel, Krishna Prasad
    Arora, Ashish
    Chandran, Arul
    [J]. JOURNAL OF CLINICAL MEDICINE, 2021, 10 (02) : 1 - 12
  • [7] Empagliflozin in patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease
    Anker, Stefan D.
    Sander, Leif-Erik
    Fitchett, David H.
    Zinman, Bernard
    Ofstad, Anne Pernille
    Wanner, Christoph
    Vedin, Ola
    Lauer, Sabine
    Verma, Subodh
    Yaggi, Henry K.
    Inzucchi, Silvio E.
    [J]. DIABETES RESEARCH AND CLINICAL PRACTICE, 2022, 186
  • [8] Chronic obstructive pulmonary disease and type 2 diabetes mellitus
    Alvarez-Sala, R.
    [J]. REVISTA CLINICA ESPANOLA, 2010, 210 (10): : 535 - 535
  • [9] EFFECTS OF PULMONARY REHABILITATION DURING HOSPITALIZATION OF PATIENTS WITH ACUTE EXACERBATION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE
    Cao, Xiaolan
    Jiang, Xiaoli
    Tong, Shuping
    Zhou, Changmei
    Chen, Bi
    [J]. ACTA MEDICA MEDITERRANEA, 2022, 38 (04): : 2363 - 2369
  • [10] Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease
    Saeed, Mohamad Isam
    Eklof, Josefin
    Achir, Imane
    Sivapalan, Pradeesh
    Meteran, Howraman
    Lokke, Anders
    Biering-Sorensen, Tor
    Knop, Filip Krag
    Jensen, Jens-Ulrik Staehr
    [J]. DIABETES OBESITY & METABOLISM, 2020, 22 (08): : 1348 - 1356